BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38935360)

  • 1. Interleukin-1 as a therapeutic target in TTP.
    Ali SA; Gardiner EE
    Blood; 2024 Jun; 143(26):2686-2688. PubMed ID: 38935360
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].
    Gabay C
    Rev Med Suisse Romande; 2000 Jun; 120(6):529-33. PubMed ID: 11014098
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute inflammatory arthritis: interleukin-1 blockade: a magic wand for gout?
    Bardin T
    Nat Rev Rheumatol; 2009 Nov; 5(11):594-6. PubMed ID: 19865087
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-1 as a target in inflammation.
    Ito Y; Kaneko N; Iwasaki T; Morikawa S; Kaneko K; Masumoto J
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):206-11. PubMed ID: 26333726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human interleukin-1 receptor antagonist is expressed in liver.
    Steinkasserer A; Estaller C; Weiss EH; Sim RB
    FEBS Lett; 1992 Sep; 310(1):60-2. PubMed ID: 1382023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native interleukin 1 inhibitors.
    Larrick JW
    Immunol Today; 1989 Feb; 10(2):61-6. PubMed ID: 2526643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interleukin 1 in the pathogenesis of rheumatoid arthritis.
    Miossec P
    Clin Exp Rheumatol; 1987; 5(4):305-8. PubMed ID: 3326690
    [No Abstract]   [Full Text] [Related]  

  • 8. The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease.
    Allan SM; Pinteaux E
    Curr Drug Targets CNS Neurol Disord; 2003 Oct; 2(5):293-302. PubMed ID: 14529361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Context-Dependent IL-1 mRNA-Destabilization by TTP Prevents Dysregulation of Immune Homeostasis Under Steady State Conditions.
    Sneezum L; Eislmayr K; Dworak H; Sedlyarov V; Le Heron A; Ebner F; Fischer I; Iwakura Y; Kovarik P
    Front Immunol; 2020; 11():1398. PubMed ID: 32733464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
    Tran AP; Edelman J
    Int J Rheum Dis; 2011 Aug; 14(3):e33-7. PubMed ID: 21816011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-1 trap. Regeneron/Novartis.
    Gabay C
    Curr Opin Investig Drugs; 2003 May; 4(5):593-7. PubMed ID: 12833655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.
    Burns JC; Koné-Paut I; Kuijpers T; Shimizu C; Tremoulet A; Arditi M
    Arthritis Rheumatol; 2017 Feb; 69(2):268-276. PubMed ID: 27792871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cytokine release inhibitors. Part II: Steroids.
    He W; Huang FC; Morytko M; Jariwala N; Yu KT
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2825-8. PubMed ID: 9873630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulating functions of tumor necrosis factor and interleukin 1 inhibitors.
    Dayer JM
    J Rheumatol Suppl; 1992 Jan; 32():59-60. PubMed ID: 1319488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A urine inhibitor of interleukin 1 activity that blocks ligand binding.
    Seckinger P; Lowenthal JW; Williamson K; Dayer JM; MacDonald HR
    J Immunol; 1987 Sep; 139(5):1546-9. PubMed ID: 2957429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel cytokine release inhibitors. Part IV: analogs of podocarpic acid.
    He W; Gavai A; Huang FC; Regan J; Hanney B; Poli G; Bruno J; Chan WK; Djuric SW; Yu KT; Zilberstein A
    Bioorg Med Chem Lett; 1999 Feb; 9(3):469-74. PubMed ID: 10091704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 Blockade: An Update on Emerging Indications.
    Mistry A; Savic S; van der Hilst JCH
    BioDrugs; 2017 Jun; 31(3):207-221. PubMed ID: 28497222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting the cytokine trap for autoimmunity.
    Dinarello CA
    Nat Med; 2003 Jan; 9(1):20-2. PubMed ID: 12514715
    [No Abstract]   [Full Text] [Related]  

  • 19. [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
    Shouval R; Livneh A; Ben-Zvi I
    Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 1, but not interleukin 1 inhibitor, is released from human monocytes by immune complexes.
    Remvig L; Thomsen BS; Baek L; Svenson M; Bendtzen K
    Scand J Immunol; 1990 Sep; 32(3):255-61. PubMed ID: 2402594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.